Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.

被引：9

作者：

Haese A. ^{[1
]}

Graefen M. ^{[1
]}

Huland H. ^{[1
]}

Lilja H. ^{[1
]}

机构：

[1] Department of Urology, University Clinic Hamburg-Eppendorf, Martinistrasse 52, Hamburg

来源：

Current Urology Reports | 2004年 / 5卷 / 3期

关键词：

Prostate Cancer; Radical Prostatectomy; Localize Prostate Cancer; Human Kallikrein; tPSA Level;

D O I：

10.1007/s11934-004-0042-6

中图分类号：

学科分类号：

摘要：

Despite its unparalleled merits for prostate cancer detection and staging, prostate-specific antigen (PSA) is not a marker for prostate cancer only, but also is expressed in benign conditions. For early detection, limitations of PSA are obvious. Its widespread use has led to an extensive amount of expensive and often unnecessary diagnostic procedures associated with significant morbidity. Total PSA derivatives may enhance the accuracy of prostate cancer diagnosis. The ratio of free-to-total PSA improves specificity while maintaining a high sensitivity for prostate cancer detection for men with a total PSA of 2.5 to 10 ng/mL. Human glandular kallikrein also has the potential to be a valuable tool in combination with total and free PSA for early diagnosis of prostate cancer. Complex PSA seems to be a reliable tool to improve specificity at high sensitivity levels in men with suspected prostate cancer (mainly in PSA levels below 4 ng/mL). Newly discovered isoforms of free PSA also may impact early detection of prostate cancer with encouraging preliminary results that warrant further clinical investigation.

引用

页码：231 / 240

页数：9

共 331 条

[81]

Richie JP(1993)The use of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 110-114

[82]

Ahmann FR(1991)Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate-specific antigen is superior to all other clinical parameters J Urol 145 313-318

[83]

Cooner WH(1996)Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate Urology 48 240-248

[84]

Mosley BR(1998)The value of the ratio of free-to-total prostate-specific antigen for staging purposes in previously untreated prostate cancer J Urol 159 2004-2007

[85]

Rutherford CL(2002)Percent free prostate-specific antigen is not an independent predictor of organ confinement or prostate-specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy J Urol 167 1306-1309

[86]

Hammerer P(2001)Value of the serum prostatespecific antigen-alpha 1-antichymotrypsin complex and its density as a predictor for the extent of prostate cancer BJU Int 88 53-57

[87]

Huland H(1998)Clinical evaluation of serum prostate-specific antigen-alpha1-antichymotrypsin complex values in diagnosis of prostate cancer: a cooperative study Int J Urol 5 48-54

[88]

Ellis WJ(2002)Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis Urology 60 10-17

[89]

Chetner MP(2001)A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy J Urol 165 857-863

[90]

Preston SD(2000)Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer J Urol 163 1491-1497

← 4 5 6 7 8 9 10 11 12 13 →